Economic evaluation and decision making: Reimbursing trastuzumab in early-stage breast cancer

PharmacoEconomics

Volumn 25, Issue 3, 2007, Pages 181-185

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEART DISEASE; HUMAN; MEDICAL DECISION MAKING; NOTE; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; NEOPLASM STAGING; RECEPTOR, ERBB-2; REIMBURSEMENT MECHANISMS;

EID: 33847763248     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725030-00001     Document Type: Note

References (17)

1. Braga S, dal Lago L, Bernard C, et al. Use of trastuzumab for the treatment of early stage breast cancer. Expert Rev Anticancer Ther 2006; 6 (8): 1153-64
2. Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer 2006; 42 (12): 1715-9
3. European Agency for the Evaluation of Medicinal Products. Committee for Medicinal Products for Human Use post-authorisation summary of opinion for Herceptin. Ref. EMEA/152318/2006 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/opinion/15231806en.pdf [Accessed 2007 Jan 25]
4. Summary of product characteristics: Herceptin® [online]. Available from URL: http://www.nice.org.uk/page.aspx?o=328491 [Accessed 2007 Feb 7]
5. Hewitt fast-tracks cancer drug to save 100 lives [press release 2005/0339]. London: Department of Health, 2005 [online]. Available from URL: http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/ PressReleasesNotices/fs/en?CONTENT_ID=4120630&chk=eihnMJ [Accessed 2006 Dec 1]
6. Herceptin for early stage breast cancer. Department of Health's Chief Executive Bulletin 294, 2005 Nov 4-10 [online]. Available from URL: http://www.dh.gov.uk/PublicationsAndStatistics/Bulletins/ChiefExecutiveBulletin/ BulletinCE/fs/en?CONTENT_ID=4122883&chk=85YQSF [Accessed 2007 Jan 25]
7. Hillner BE. Clinical and cost-effectiveness implications of the adjuvant trastuzumab in HER2+ breast cancer trials [abstract no. 5040]. San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio [online]. Available from URL: http://www.abstracts2view.com/sabcs05 [Accessed 2006 Dec 19]
8. Ragaz J, Spinelli JJ. Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa) [abstract no. 2029]. San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio [online]. Available from URL: http://www.abstracts2view.com/sabcs05 [Accessed 2006 Dec 19]
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84
11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S5
12. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20
13. Herceptin status unchanged following further PTAC advice [media release]. Wellington: Pharmaceutical Management Agency, 2006 Oct 16 [online]. Available from URL: http://www.pharmac.govt.nz/pdf/161006.pdf [Accessed 2006 Dec 4]
14. Listing of Herceptin on the PBS [fact sheet]. Canberra: Australian Government Department of Health and Ageing, 2006 Oct 1 [online]. Available from URL: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/herceptin- govtdecision.htm [Accessed 2006 Dec 4]
15. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer: NICE technology appraisal guidance 107 [online]. Available from URL: http://www.nice.org.uk/guidance/TA107/guidance/pdf/English [Accessed 2006 Dec 5]
16. Scottish Medicines Consortium. Trastuzumab 150mg vial (Herceptin®). No. 278/06 [online]. Available from URL: http://www.scottishmedicines.org.uk/ press/detail.asp?id=954http [Accessed 2006 Dec 5]
17. Huybrechts M, Hulstaert F, Neyt M, et al. Trastuzumab in early-stage breast cancer. KCE report 34A. Brussels: Belgian Health Care Knowledge Centre, 2006